ArticleCureus2026
Acute Monoblastic Leukemia (AML-M5) Presenting As Tonsillar Hypertrophy: An Unusual ENT Presentation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute monoblastic leukemia (AML-M5) is a rare subtype of acute leukemia in children and may present with extramedullary involvement. We report the case of a nine-year-old boy with trisomy 21 who was referred to the otorhinolaryngology department for severe obstructive sleep apnea syndrome (OSAS). Clinical examination revealed marked bilateral tonsillar hypertrophy without associated signs of infection. Preoperative laboratory investigations performed prior to planned adenotonsillectomy demonstrated bicytopenia and circulating blasts on the peripheral blood smear. Bone marrow aspiration confirmed the diagnosis of AML, subtype M5. The patient was managed in the pediatric hematology and oncology department at Harouchi University Hospital in Casablanca. Following initiation of chemotherapy, a spontaneous regression of the tonsillar hypertrophy was observed, confirming its leukemic origin. This case highlights the importance of considering an underlying hematologic malignancy in cases of atypical tonsillar hypertrophy, particularly in children with known risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.